People
On March 25, the American Medical Association, American Pharmacist Association and Americans Society of Health-System Pharmacists issued a statement in response to media reports that physicians and pharmacists were hoarding supplies of the drugs for their own use.
“Companies active in the fight against COVID-19 will have plenty of funding, and those targeting severe unmet needs will weather the storm better than others. But, for the rest, it will be rough for the next 12 months,” said Otello Stampacchia, founder of Omega Funds.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Results from the trial, which will begin dosing on April 6, aren’t likely until September.
In addition to the impact on conferences and large meetings, many companies have implemented restrictions on face-to-face meetings between sales reps and clients.
Doudna announced she is converting a 2,500-square-foot scientific lab at Berkeley’s Innovative Genomics Institute into a lab for testing for the novel coronavirus that causes COVID-19.
First uses are envisioned as treatments for severely ill coronavirus patients and individuals at high risk of contracting the disease, including healthcare professionals.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
PRESS RELEASES